Allergies: review of the evidence.
Recent changes in our perceptions of allergic IgE-mediated disease are based on evidence indicating a prominent role for both the early- and late-phase responses. The relative importance of the late-phase inflammatory reaction suggests the need for a critical re-evaluation of both diagnosis and therapy. Skin testing remains the gold standard of laboratory procedures despite new technology. Corticosteroids, acting primarily as potent anti-inflammatory agents affecting the late response, are now seen as primary therapy for allergic disease. Other drugs without anti-inflammatory properties will likely play a secondary role in future. The use of immunotherapy is also changing; this treatment may play a more prominent clinical role as a modulator of the immune response, particularly the latephase reaction.
P
P
Small
J Allergy Clin Immunol. 1985 May;75(5):568-72
2985677
J Allergy Clin Immunol. 1987 May;79(5):734-40
3106449
J Allergy Clin Immunol. 1988 Nov;82(5 Pt 2):927-34
3057045
J Clin Invest. 1976 Aug;58(2):408-20
783199
Am Rev Respir Dis. 1987 Sep;136(3):740-51
3115156
Ann Allergy. 1985 Nov;55(5):747-52
2865918
J Allergy Clin Immunol. 1988 Sep;82(3 Pt 1):389-97
3049744